Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Eculizumab for the treatment of dense-deposit disease.

Vivarelli M, Pasini A, Emma F.

N Engl J Med. 2012 Mar 22;366(12):1163-5. doi: 10.1056/NEJMc1111953. No abstract available.

2.

Eculizumab in a patient with dense-deposit disease.

Daina E, Noris M, Remuzzi G.

N Engl J Med. 2012 Mar 22;366(12):1161-3. doi: 10.1056/NEJMc1112273. No abstract available. Erratum in: N Engl J Med. 2012 Apr 12;366(15):1454.

3.

Eculizumab and refractory membranoproliferative glomerulonephritis.

Radhakrishnan S, Lunn A, Kirschfink M, Thorner P, Hebert D, Langlois V, Pluthero F, Licht C.

N Engl J Med. 2012 Mar 22;366(12):1165-6. doi: 10.1056/NEJMc1106619. No abstract available.

4.

Eculizumab for dense deposit disease and C3 glomerulonephritis.

Bomback AS, Smith RJ, Barile GR, Zhang Y, Heher EC, Herlitz L, Stokes MB, Markowitz GS, D'Agati VD, Canetta PA, Radhakrishnan J, Appel GB.

Clin J Am Soc Nephrol. 2012 May;7(5):748-56. doi: 10.2215/CJN.12901211. Epub 2012 Mar 8.

5.

Pathology after eculizumab in dense deposit disease and C3 GN.

Herlitz LC, Bomback AS, Markowitz GS, Stokes MB, Smith RN, Colvin RB, Appel GB, D'Agati VD.

J Am Soc Nephrol. 2012 Jul;23(7):1229-37. doi: 10.1681/ASN.2011121186. Epub 2012 Jun 7.

6.

Anti-complement therapy for glomerular diseases.

Bomback AS.

Adv Chronic Kidney Dis. 2014 Mar;21(2):152-8. doi: 10.1053/j.ackd.2013.12.001. Review.

PMID:
24602464
7.

New aspects of membranoproliferative glomerulonephritis.

Manenti L, Vaglio A, Buzio C.

N Engl J Med. 2012 Jul 5;367(1):86; author reply 86-7. doi: 10.1056/NEJMc1205019#SA1. No abstract available.

PMID:
22762333
8.

Monoclonal antibodies for the treatment of the C3 glomerulopathies.

Beck LH Jr.

Clin J Am Soc Nephrol. 2012 May;7(5):704-6. doi: 10.2215/CJN.03010312. Epub 2012 Apr 12. No abstract available.

9.

Eculizumab and recurrent C3 glomerulonephritis.

Gurkan S, Fyfe B, Weiss L, Xiao X, Zhang Y, Smith RJ.

Pediatr Nephrol. 2013 Oct;28(10):1975-81. doi: 10.1007/s00467-013-2503-y. Epub 2013 May 22.

10.

Recurrent dense deposit disease after renal transplantation: an emerging role for complementary therapies.

McCaughan JA, O'Rourke DM, Courtney AE.

Am J Transplant. 2012 Apr;12(4):1046-51. doi: 10.1111/j.1600-6143.2011.03923.x. Epub 2012 Jan 10.

11.

Eculizumab in dense-deposit disease after renal transplantation.

Sánchez-Moreno A, De la Cerda F, Cabrera R, Fijo J, López-Trascasa M, Bedoya R, Rodríguez de Córdoba S, Ybot-González P.

Pediatr Nephrol. 2014 Oct;29(10):2055-9. doi: 10.1007/s00467-014-2839-y. Epub 2014 Jun 8.

PMID:
24908321
12.

Eculizumab therapy in a patient with dense-deposit disease associated with partial lipodystropy.

Ozkaya O, Nalcacioglu H, Tekcan D, Genc G, Meydan BC, Ozdemir BH, Baysal MK, Keceligil HT.

Pediatr Nephrol. 2014 Jul;29(7):1283-7. doi: 10.1007/s00467-013-2748-5. Epub 2014 Jan 26.

PMID:
24464478
13.

Rituximab fails where eculizumab restores renal function in C3nef-related DDD.

Rousset-Rouvière C, Cailliez M, Garaix F, Bruno D, Laurent D, Tsimaratos M.

Pediatr Nephrol. 2014 Jun;29(6):1107-11. doi: 10.1007/s00467-013-2711-5. Epub 2014 Jan 10.

PMID:
24408225
14.

Eculizumab in the treatment of membranoproliferative glomerulonephritis.

Bomback AS.

Nephron Clin Pract. 2014;128(3-4):270-6. doi: 10.1159/000368592. Epub 2014 Nov 11. Review.

15.

Treatment of C3 glomerulopathy with complement blockers.

Vivarelli M, Emma F.

Semin Thromb Hemost. 2014 Jun;40(4):472-7. doi: 10.1055/s-0034-1375299. Epub 2014 May 5. Review.

PMID:
24799307
16.

Eculizumab treatment for rescue of renal function in IgA nephropathy.

Rosenblad T, Rebetz J, Johansson M, Békássy Z, Sartz L, Karpman D.

Pediatr Nephrol. 2014 Nov;29(11):2225-8. doi: 10.1007/s00467-014-2863-y. Epub 2014 Jun 13.

PMID:
24924752
17.

Membranoproliferative glomerulonephritis in a girl and her mother.

Motoyama O, Sakai K, Ohashi Y, Mizuiri S, Hatori T, Iitaka K, Koitabashi Y.

Clin Exp Nephrol. 2009 Feb;13(1):77-80. doi: 10.1007/s10157-008-0070-5. Epub 2008 Jul 19.

PMID:
18641916
18.

Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies.

Servais A, Noël LH, Roumenina LT, Le Quintrec M, Ngo S, Dragon-Durey MA, Macher MA, Zuber J, Karras A, Provot F, Moulin B, Grünfeld JP, Niaudet P, Lesavre P, Frémeaux-Bacchi V.

Kidney Int. 2012 Aug;82(4):454-64. doi: 10.1038/ki.2012.63. Epub 2012 Mar 28.

PMID:
22456601
19.

Drugs that inhibit complement.

Schrezenmeier H, Höchsmann B.

Transfus Apher Sci. 2012 Feb;46(1):87-92. doi: 10.1016/j.transci.2011.11.012. Epub 2011 Dec 13. Review.

PMID:
22169380
20.

Membranoproliferative glomerulonephritis.

Alchi B, Jayne D.

Pediatr Nephrol. 2010 Aug;25(8):1409-18. doi: 10.1007/s00467-009-1322-7. Epub 2009 Nov 12. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk